Clinical Trial Contact Request

A NOVEL MULTIPLEX IMMUNOASSAY FOR PREDICTING INTRAVESICAL BCG RESPONSE IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER